Sugi Predict

Sugi Predict / Compounds / SCHEMBL923056

SCHEMBL923056

SCHEMBL923056

CCNC1=NN=C/C1=N\Nc1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 16/20 0.42
▸ CA1 P00915 14/20 0.42
▸ CA9 Q16790 13/20 0.42
▸ KMT2A Q03164 2/20 0.40
▸ CA12 O43570 10/20 0.40
▸ CA4 P22748 1/20 0.40
▸ CA6 P23280 1/20 0.40
▸ CA5A P35218 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ CA5B Q9Y2D0 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ EIF2AK2 P19525 1/20 0.39
▸ CACNA1B Q00975 1/20 0.37
▸ APBA1 Q02410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923057 1.00 CA2 (0.42) CA2CA1CA9KMT2ACA12
SCHEMBL922323 0.79 CA2 (0.46) CA2CA1CA9KMT2ACA12
SCHEMBL922325 0.79 CA2 (0.46) CA2CA1CA9KMT2ACA12
SCHEMBL922310 0.74 MEN1 (0.32) KMT2AMAPTMEN1
SCHEMBL5803415 0.71 CA2 (0.65) CA2CA1CA9CA12CA4
SCHEMBL924334 0.66 EIF2AK2 (0.55) CA2CA1CA9KMT2ACA12
SCHEMBL923232 0.63 CYP2C9 (0.54) CA2CA1CA9KMT2ACA12
SCHEMBL14467517 0.63 CA2 (0.59) CA2CA1CA9KMT2ACA12
Toluene SCHEMBL27520035 0.62 CA1 (0.60) CA2CA1CA9CA12CA4
SCHEMBL11755122 0.62 CA2 (0.67) CA2CA1CA9KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 — — US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 — — US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 — — US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 — — US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 CA2 1604/4885CA1 4214/4885CA9 3653/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 CA2 1604/4885CA1 4214/4885CA9 3653/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC CA2 2257/4885CA1 4303/4885CA9 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.